Dolly Not Yet Turned To Lolly

more+
less-

As public markets remain tricky for biotech companies M&A activity in the sector has surged. But will this hyper-activity prevent Europe from producing the European equivalent of Genzyme or Amgen?

A recent article in the London Times newspaper lead with the headline “Hello Dolly, but things aren’t looking swell”. It is true that the European biotech sector continues to face some serious challenges in accessing capital. In addition, there is a feeling that a number of companies, particularly some smaller cap companies listed on AIM, remain undervalued and under-capitalised. However;

companies, both public and private, have increasingly taken advantage of the concern that larger pharmaceutical companies have - that their development pipelines are not sufficiently advanced to replace existing products that they will lose patent protection. This has lead to the completion of a number of high profile M&A and licensing deals. Thegood news is that the sector has seen a number

of exits where Pharma has been willing to part with cash to secure exclusive access to technology either through M&A or partnering transactions. Does biotech face a challenging environment? The answer is yes. Can biotech still succeed in the European market? Yes!

LOADING PDF: If there are any problems, click here to download the file.

Published In: Business Organization Updates, International Trade Updates, Mergers & Acquisitions Updates, Science, Computers & Technology Updates

DISCLAIMER: Because of the generality of this update, the information provided herein may not be applicable in all situations and should not be acted upon without specific legal advice based on particular situations.

© Morrison & Foerster LLP | Attorney Advertising

Don't miss a thing! Build a custom news brief:

Read fresh new writing on compliance, cybersecurity, Dodd-Frank, whistleblowers, social media, hiring & firing, patent reform, the NLRB, Obamacare, the SEC…

…or whatever matters the most to you. Follow authors, firms, and topics on JD Supra.

Create your news brief now - it's free and easy »